Amgen Inc.

Amgen Research (munich) Gmbh

Amgen Research Gmbh

Brian Mingtung Chan

Yang Li

Chadwick Terence King

Shouhua Xiao

Dineli Wickramasinghe

Zheng Pan

M Shawn Jeffries

Peter Kufer

Tobias Raum

Patrick Hoffmann

Doris Rau

Ralf Lutterbüse

Holger Wesche

Bryan D Lemon

Roman Kischel

Derek Evan Piper

Ralf Lutterbuese

Christopher Murawsky

Jun Zhang

Peter Coward

Paul Nioi

Fernando Garces

Shawn M Jeffries

Provided are antibody constructs comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Also provided are nucleic acids encoding the antibody constructs, vectors comprising the nucleic acids, and host cells transformed or transfected with the vectors. Further provided are a process for the production of the antibody constructs, methods of using the antibody constructs and a kit comprising the antibody constructs.

Antibody constructs for CDH19 and CD3

Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

Anti-ASGR-1 monoclonal inhibitory antibodies

The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.

The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct.

Antibodies targeting CDH19 for melanoma

Growing community of inventors

Coquitlam, Canada

Brian Mingtung Chan